Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites
CONCLUSIONS: Blockade of PD-L1/CXCL10 axis or MDSC infiltration during radiation can enhance abscopal tumor control and reduce metastasis.PMID:38427437 | DOI:10.1158/1078-0432.CCR-23-3206 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 1, 2024 Category: Cancer & Oncology Authors: Yuzhu Hou Kaiting Yang Liangliang Wang Jiaai Wang Xiaona Huang Andras Piffko Sean Z Luo Xinshuang Yu Enyu Rao Carlos Martinez Jason Bugno Matthias Mack Everett E Vokes Sean P Pitroda Steven J Chmura Ralph R Weichselbaum Hua Laura Liang Source Type: research
Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites
CONCLUSIONS: Blockade of PD-L1/CXCL10 axis or MDSC infiltration during radiation can enhance abscopal tumor control and reduce metastasis.PMID:38427437 | DOI:10.1158/1078-0432.CCR-23-3206 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 1, 2024 Category: Cancer & Oncology Authors: Yuzhu Hou Kaiting Yang Liangliang Wang Jiaai Wang Xiaona Huang Andras Piffko Sean Z Luo Xinshuang Yu Enyu Rao Carlos Martinez Jason Bugno Matthias Mack Everett E Vokes Sean P Pitroda Steven J Chmura Ralph R Weichselbaum Hua Laura Liang Source Type: research
Improved risk stratification scheme for mismatch repair proficient stage II colorectal cancers using the digital pathology biomarker QuantCRC
CONCLUSIONS: Incorporation of QuantCRC into risk stratification provides a powerful predictor of RFS that has potential to guide subsequent treatment and surveillance for stage II MMRP CRCs.PMID:38421684 | DOI:10.1158/1078-0432.CCR-23-3211 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 29, 2024 Category: Cancer & Oncology Authors: Christina Wu Reetesh K Pai Heidi Kosiorek Imon Banerjee Ashlyn Pfeiffer Catherine E Hagen Christopher P Hartley Rondell P Graham Mohamad B Sonbol Tanios Bekaii-Saab Hao Xie Frank A Sinicrope Bhavik Patel Thomas Westerling-Bui Sameer Shivji James Conner Ca Source Type: research
Improved risk stratification scheme for mismatch repair proficient stage II colorectal cancers using the digital pathology biomarker QuantCRC
CONCLUSIONS: Incorporation of QuantCRC into risk stratification provides a powerful predictor of RFS that has potential to guide subsequent treatment and surveillance for stage II MMRP CRCs.PMID:38421684 | DOI:10.1158/1078-0432.CCR-23-3211 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 29, 2024 Category: Cancer & Oncology Authors: Christina Wu Reetesh K Pai Heidi Kosiorek Imon Banerjee Ashlyn Pfeiffer Catherine E Hagen Christopher P Hartley Rondell P Graham Mohamad B Sonbol Tanios Bekaii-Saab Hao Xie Frank A Sinicrope Bhavik Patel Thomas Westerling-Bui Sameer Shivji James Conner Ca Source Type: research
Ataxia-Telangiectasia Mutated (ATM) loss of function displays variant and tissue-specific differences across tumor types
CONCLUSIONS: These data help to better define ATM LOF across tumor types in order to optimize patient selection and improve molecularly targeted therapeutic approaches for patients with ATM LOF cancers.PMID:38416404 | DOI:10.1158/1078-0432.CCR-23-1763 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 28, 2024 Category: Cancer & Oncology Authors: Patrick G Pilie Virginia Giuliani Wei-Lien Wang Daniel J McGrail Christopher A Bristow Natalie Y L Ngoi Keith Kyewalabye Khalida M Wani Hung Le Erick Campbell Nora S S ánchez Dong Yang Jinesh S Gheeya Rohit Vivek Goswamy Vijaykumar Holla Kenna Rael Shaw Source Type: research
Molecular profiling and the impact of treatment on outcomes in adenoid cystic carcinoma (ACC) type-I and II
CONCLUSIONS: We confirmed the previously reported associations with MYC and TP63 in the prognostically relevant subgroups of ACC-I and II, respectively, and report immunologic differences among these subtypes. Survival outcomes are comparatively worse in ACC-I regardless of treatment type.PMID:38416410 | DOI:10.1158/1078-0432.CCR-23-3182 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 28, 2024 Category: Cancer & Oncology Authors: Glenn J Hanna Punita Grover Andrew Elliott Julie McGrath Joanne Xiu Ammar Sukari Jennifer M Johnson Trisha Wise-Draper Source Type: research
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma
CONCLUSIONS AND RELEVANCE: In this post hoc partitioned survival analysis, TFS and TFS without toxicity appeared similar in the IO-TKI group compared to the SUN group. These findings may reflect continuation of TKI until progression per protocol design in all trials and discontinuation of IO after 2 years in 2 trials.PMID:38416426 | DOI:10.1158/1078-0432.CCR-23-3719 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 28, 2024 Category: Cancer & Oncology Authors: Elaine Chang Jiaxi Zhou Chi Song Haley Gittleman Laura Fernandes Chana Weinstock Michael B Atkins Sundeep Agrawal Rajeshwari Sridhara Nicole Gormley Shenghui Tang Daniel L Suzman Laleh Amiri-Kordestani Paul G Kluetz Richard Pazdur Brian I Rini David F McD Source Type: research
All that is small is not a small cell carcinoma: Thoracic SMARCA4 undifferentiated tumors masquerading as SCLC
Clin Cancer Res. 2024 Feb 28. doi: 10.1158/1078-0432.CCR-24-0227. Online ahead of print.ABSTRACTSmall cell lung carcinoma (SCLC) cell lines have been widely utilized as a preclinical model of this highly aggressive disease. However, since their creation decades ago, novel tumor entities have been defined that may clinicopathologically mimic SCLC, which notably includes thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT). Multi-omic reassessment of the presumed SCLC cell lines with high YAP1 expression reveals that nearly all of these tumors represent unsuspected SMARCA4-UT.PMID:38416596 | DOI:10.1158/1078-0432.C...
Source: Clinical Cancer Research - February 28, 2024 Category: Cancer & Oncology Authors: Natasha Rekhtman Source Type: research
Adult-onset cancer predisposition syndromes in children and adolescents - to test or not to test?
Clin Cancer Res. 2024 Feb 27. doi: 10.1158/1078-0432.CCR-23-3683. Online ahead of print.ABSTRACTWith the increasing use of comprehensive germline genetic testing of children and adolescents with cancer, it has become evident that pathogenic variants (PVs) in adult-onset cancer predisposition genes (aoCPGs) underlying adult-onset cancer predisposition syndromes (aoCPS) such as Lynch syndrome or hereditary breast and ovarian cancer are enriched and reported in one to two percent of children and adolescents with cancer. However, the causal relationship between PVs in aoCPGs and childhood cancer is still under investigation. T...
Source: Clinical Cancer Research - February 27, 2024 Category: Cancer & Oncology Authors: Christian P Kratz Philip J Lupo Kristin Zelley Jaclyn Schienda Kim E Nichols Douglas R Stewart David Malkin Garrett M Brodeur Kara Maxwell Sharon E Plon Michael F Walsh Source Type: research
Adult-onset cancer predisposition syndromes in children and adolescents - to test or not to test?
Clin Cancer Res. 2024 Feb 27. doi: 10.1158/1078-0432.CCR-23-3683. Online ahead of print.ABSTRACTWith the increasing use of comprehensive germline genetic testing of children and adolescents with cancer, it has become evident that pathogenic variants (PVs) in adult-onset cancer predisposition genes (aoCPGs) underlying adult-onset cancer predisposition syndromes (aoCPS) such as Lynch syndrome or hereditary breast and ovarian cancer are enriched and reported in one to two percent of children and adolescents with cancer. However, the causal relationship between PVs in aoCPGs and childhood cancer is still under investigation. T...
Source: Clinical Cancer Research - February 27, 2024 Category: Cancer & Oncology Authors: Christian P Kratz Philip J Lupo Kristin Zelley Jaclyn Schienda Kim E Nichols Douglas R Stewart David Malkin Garrett M Brodeur Kara Maxwell Sharon E Plon Michael F Walsh Source Type: research
First-in-Human Study of the Ataxia Telangiectasia and Rad3-related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
CONCLUSIONS: Tuvusertib demonstrated manageable safety and exposure-related target engagement. Further clinical evaluation of tuvusertib is ongoing.PMID:38407317 | DOI:10.1158/1078-0432.CCR-23-2409 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 26, 2024 Category: Cancer & Oncology Authors: Timothy A Yap Anthony W Tolcher Ruth Plummer Jatinder Kaur Mukker Marta Enderlin Christine Hicking Thomas Grombacher Giuseppe Locatelli Zoltan Szucs Ioannis Gounaris Johann S de Bono Source Type: research
First-in-Human Study of the Ataxia Telangiectasia and Rad3-related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
CONCLUSIONS: Tuvusertib demonstrated manageable safety and exposure-related target engagement. Further clinical evaluation of tuvusertib is ongoing.PMID:38407317 | DOI:10.1158/1078-0432.CCR-23-2409 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 26, 2024 Category: Cancer & Oncology Authors: Timothy A Yap Anthony W Tolcher Ruth Plummer Jatinder Kaur Mukker Marta Enderlin Christine Hicking Thomas Grombacher Giuseppe Locatelli Zoltan Szucs Ioannis Gounaris Johann S de Bono Source Type: research
Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma
CONCLUSIONS: CAR-TEAM cells enable modification of tumor stroma, leading to increased elimination of PDAC tumors. This approach represents a promising treatment option for pancreatic cancer.PMID:38393682 | DOI:10.1158/1078-0432.CCR-23-3841 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 23, 2024 Category: Cancer & Oncology Authors: Marc Wehrli Samantha Guinn Filippo Birocchi Adam Kuo Yi Sun Rebecca C Larson Antonio J Almazan Irene Scarf ò Amanda A Bouffard Stefanie R Bailey Praju Vikas Anekal Paula Montero Lopis Linda T Nieman Yuhui Song Katherine H Xu Trisha R Berger Michael C Kan Source Type: research
Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
CONCLUSIONS: Innate immune impairment and infection susceptibility in CLL patients were restored in parallel during targeted therapy. Thus, targeted treatment may reduce the risk of infections in CLL, as currently under investigation in the PreVent-ACaLL phase 2 trial of acalabrutinib+venetoclax for high risk CLL (NCT03868722).PMID:38393694 | DOI:10.1158/1078-0432.CCR-23-2522 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 23, 2024 Category: Cancer & Oncology Authors: Rebecca Svanberg Teglgaard Hanne Vibeke Marquart Hans Jakob Hartling Jakob Thaning Bay Caspar da Cunha-Bang Christian Brieghel Tereza Faitov á Lisbeth Enggaard Arnon P Kater Mark-David Levin Sabina Kersting Sisse Rye Ostrowski Carsten U Niemann Source Type: research
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
CONCLUSIONS: Belzutifan continued to show robust activity and manageable safety in VHL disease-associated pNETs.PMID:38393723 | DOI:10.1158/1078-0432.CCR-23-2592 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 23, 2024 Category: Cancer & Oncology Authors: Tobias Else Eric Jonasch Othon Lliopoulos Kathryn E Beckermann Vivek Narayan Benjamin L Maughan Stephane Oudard Jodi K Maranchie Ane B Iversen Cynthia Muller Goldberg Wei Fu Rodolfo F Perini Yanfang Liu W Marston Linehan Ramaprasad Srinivasan Source Type: research
